Regeneron (REGN) AI Stock Analysis

• Market Cap: $59.14B
• Dividend Yield: 0.64%
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): 13.9
• Beta (1Y): 0.72
• Revenue Growth: 7.52%
• EPS Growth: 15.65%
• Country: US
• Employees: 15,158
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 8.22
• Shares Outstanding: 106,148,350
• 10 Day Avg. Volume: 850,843
• 30 Day Avg. Volume: 1,367,287
• PEG Ratio: 5.62
• Price to Book (P/B): 1.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 17.92
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 0.97
• Enterprise Value/Gross Profit: 4.49
• Enterprise Value/Ebitda: 2.81
• 1Y Price Target: $720.18
• Price Target Upside: 28.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 25

• Rating: 72 Outperform
• Price Target: $583.00 ▲(4.15%Upside)

Regeneron's robust financial performance and strong product pipeline are key strengths, contributing positively to the overall score. However, technical analysis indicates bearish momentum, and the challenges highlighted in the earnings call, such as declining EYLEA sales, present significant risks. Fair valuation supports the score but does not overshadow existing challenges.

Positive Factors

FDA Approvals

FDA approval of linvoseltamab for adult patients with relapsed or refractory multiple myeloma is expected to boost the company's prospects.

Patent Protection

New Dupixent US patent extends protection to September 2033, safeguarding it from biosimilar competition and supporting the company's market position.

Pipeline Potential

The investment community underappreciates the potential for REGN’s novel blood thinner programs, which have peak potential sales of $40B if they can generate the same efficacy as existing therapies with less bleeding risk.

Negative Factors

Eylea Sales Pressure

The mix of branded and biosimilar competition as well as patient affordability will continue to pressure Eylea sales.

Investor Concerns

Investor concerns remain due to the lack of a randomized controlled trial for the monthly dosing of Eylea HD.

Market Competition

The 4L+ MM market is crowded with several approved and investigational therapies.

Regeneron Business Overview & Revenue Model

Company Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

How the Company Makes Money

Regeneron generates revenue primarily through the sale of its pharmaceutical products, with key revenue streams including sales of EYLEA, Dupixent, and Libtayo. The company benefits from strategic collaborations and partnerships with other pharmaceutical firms to co-develop and commercialize certain drugs, which contribute to its earnings through royalties and shared profits. Additionally, Regeneron engages in research and development collaborations with partners like Sanofi, which help fund its innovation pipeline and expand its market reach. The company's financial performance is also bolstered by its proprietary VelociSuite technologies, which enhance drug discovery and development efficiency, thus leading to potential licensing opportunities.

Regeneron Financial Statement Overview

Summary

Regeneron demonstrates strong financial health with robust profitability, a solid balance sheet, and effective cash flow management. The company maintains high margins and low leverage, ensuring stability and resilience.

Income Statement

Regeneron's income statement shows strong profitability with a consistent gross profit margin of over 85% and a net profit margin of approximately 32% in the TTM period. Despite a slight decline in revenue from the previous year, the company maintains robust EBIT and EBITDA margins, indicating efficient operations.

Balance Sheet

The balance sheet reveals a solid financial position with a low debt-to-equity ratio, indicating prudent financial management. The equity ratio remains strong at over 78% in the TTM, reflecting financial stability. High levels of cash and short-term investments further bolster Regeneron's financial strength.

Cash Flow

Regeneron demonstrates solid cash flow management with a high operating cash flow to net income ratio, indicating effective conversion of earnings into cash. Although there is a slight decline in free cash flow growth, the company maintains a healthy free cash flow to net income ratio, ensuring liquidity and flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.09B	14.20B	13.12B	12.17B	16.07B	8.50B
Gross Profit	11.96B	12.23B	11.30B	10.61B	13.63B	7.38B
EBITDA	4.98B	5.32B	4.69B	5.34B	9.28B	3.90B
Net Income	4.50B	4.41B	3.95B	4.34B	8.08B	3.51B
Balance Sheet
Total Assets	37.55B	37.76B	33.08B	29.21B	25.43B	17.16B
Cash, Cash Equivalents and Short-Term Investments	8.35B	9.01B	10.84B	14.33B	12.53B	6.72B
Total Debt	2.70B	2.70B	2.70B	2.70B	2.70B	2.70B
Total Liabilities	8.16B	8.41B	7.11B	6.55B	6.67B	6.14B
Stockholders Equity	29.39B	29.35B	25.97B	22.66B	18.77B	11.03B
Cash Flow
Free Cash Flow	3.02B	3.66B	3.67B	4.42B	6.53B	2.00B
Operating Cash Flow	3.95B	4.42B	4.59B	5.01B	7.08B	2.62B
Investing Cash Flow	-133.50M	-2.47B	-3.19B	-3.78B	-5.38B	-70.60M
Financing Cash Flow	-3.34B	-2.20B	-1.79B	-1.01B	-1.01B	-1.97B

Regeneron Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 559.76
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REGN, the sentiment is Neutral. The current price of 559.76 is above the 20-day moving average (MA) of 528.71, above the 50-day MA of 547.93, and below the 200-day MA of 702.87, indicating a neutral trend. The MACD of 2.69 indicates Negative momentum. The RSI at 60.39 is Neutral, neither overbought nor oversold. The STOCH value of 81.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for REGN.

Regeneron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCY	74 Outperform	$13.10B	212.62	0.47%	―	17.13%	-88.78%
REGN	72 Outperform	$59.14B	13.94	15.96%	0.64%	7.52%	15.65%
GMAB	72 Outperform	$13.20B	12.27	22.69%	―	25.11%	46.46%
ARGX	68 Neutral	$33.22B	40.55	17.33%	―	78.01%	―
ALNY	66 Neutral	$41.40B	―	-414.62%	―	17.21%	21.16%
BNTX	58 Neutral	$26.87B	―	-3.87%	―	0.58%	-764.64%
Sector *	46 Neutral	C$200.35M	-3.25	-23.22%	2.71%	21.07%	-1.26%

Regeneron Corporate Events

Regeneron Shareholders Approve Key Proposals at 2025 Meeting

At the 2025 Annual Meeting of Shareholders held on June 13, Regeneron Pharmaceuticals’ shareholders voted on several key proposals. The election of Class I directors was confirmed, with nominees set to serve until the 2028 meeting. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. Additionally, an advisory vote approved the executive compensation package. A significant amendment to declassify the board of directors was passed, while proposals to eliminate supermajority vote requirements for certain amendments to the company’s Certificate of Incorporation were not approved.

The most recent analyst rating on (REGN) stock is a Hold with a $940.00 price target. To see the full list of analyst forecasts on Regeneron stock, see the REGN Stock Forecast page.